Skip to main content

Table 1 Effect of different types of stem cells on biochemical measurements (n = 20 and n = 5 for day subgroups, mean ± SD)

From: Comparative study of allogenic and xenogeneic mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague-Dawley rats

  Group I Group II Group III Group IV Group V Group VI
negative control cisplatin ‘CDDP’-treated cisplatin + rBMSCs-treated cisplatin + hADSCs-treated cisplatin + hAFSCs-treated cisplatin + DMEM culture media-treated
Sr. Cr. (mg/dL)
 Day 4 0.40 ± 0.12 1.92 ± 0.03a 0.92 ± 0.05ab 0.97 ± 0.02ab 1.02 ± 0.08ab 1.88 ± 0.10acde
 Day 7 0.37 ± 0.12 1.61 ± 0.05a 0.79 ± 0.04ab 0.87 ± 0.06ab 0.85 ± 0.07ab 1.63 ± 0.03acde
 Day 11 0.40 ± 0.11 1.00 ± 0.07a 0.67 ± 0.1ab 0.72 ± 0.05ab 0.70 ± 0.06ab 1.02 ± 0.10acde
 Day 30 0.39 ± 0.10 0.77 ± 0.03 a 0.52 ± 0.06ab 0.58 ± 0.06ab 0.58 ± 0.05ab 0.81 ± 0.04acde
BUN (mg/dL)
 Day 4 18.6 ± 1.14 85.6 ± 1.67a 32.0 ± 1.58ab 30.2 ± 0.83ab 34.4 ± 1.14ab 85.4 ± 1.14acde
 Day 7 18.2 ± 1.48 55.2 ± 1.30a 27.2 ± 1.30ab 27.8 ± 1.30ab 28.0 ± 1.22ab 53.8 ± 0.84acde
 Day 11 17.2 ± 1.48 32.3 ± 1.48a 24.2 ± 0.83ab 24.2 ± 1.30ab 24.4 ± 0.89ab 32.4 ± 1.51acde
 Day 30 18.0 ± 1.58 26.4 ± 0.55a 22.2 ± 0.83ab 22.4 ± 0.89ab 23.2 ± 0.84ab 26.2 ± 0.83acde
Cr. Cl. (mL/min/100 gm)
 Day 4 1.62 ± 0.44 0.007 ± 0.001a 0.021 ± 0.005a 0.021 ± 0.006a 0.018 ± 0.006a 0.008 ± 0.001a
 Day 7 1.78 ± 0.55 0.014 ± 0.001a 0.052 ± 0.008a 0.048 ± 0.001a 0.045 ± 0.001a 0.012 ± 0.002a
 Day 11 1.86 ± 0.56 0.05 ± 0.01a 0.07 ± 0.01a 0.06 ± 0.01a 0.06 ± 0.007a 0.05 ± 0.013a
 Day 30 1.76 ± 0.55 0.36 ± 0.17a 0.92 ± 0.23a 0.89 ± 0.15a 1.00 ± 0.14ab 0.46 ± 0.26a
  1. Values are expressed as mean ± SD. A significant difference (P < 0.05) between different groups was done by Bonferroni post hoc for multiple comparisons
  2. rBMSCs rat bone marrow stem cells, hADSCs human adipose tissue-derived stem cells, hAFSCs human amniotic fluid-derived stem cells, DMEM Dulbecco’s modified Eagle’s medium, Sr. Cr. serum creatinine, BUN blood urea nitrogen, Cr. Cl. creatinine clearance
  3. aSignificant difference vs. negative control group bSignificant difference vs. cisplatin-treated group cSignificant difference vs. cisplatin + rBMSCs-treated group dSignificant difference vs. cisplatin + hADSCs-treated group eSignificant difference vs. cisplatin + hAFSCs-treated group